Patents by Inventor Ziping Wei

Ziping Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240342304
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 17, 2024
    Inventors: Yuhong Zhou, Ziping Wei
  • Patent number: 11951173
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: April 9, 2024
    Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
    Inventors: Yuhong Zhou, Ziping Wei
  • Publication number: 20240075154
    Abstract: An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 7, 2024
    Inventors: Bing XIA, Yuhong ZHOU, Ziping WEI, Jianfeng YANG
  • Publication number: 20240009318
    Abstract: The present invention provides isolated antibodies that bind to the human EGFR protein, and ADCs of the antibodies. Pharmaceutical compositions including the antibodies and ADCs, and methods of treating cancer are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 11, 2024
    Inventors: Bing XIA, Yuhong ZHOU, Ziping WEI, Lixia CAO, Fangdun JIANG
  • Publication number: 20240002527
    Abstract: Isolated anti-human CD73 antibody includes two heavy chains each including a hinge region comprising an amino acid sequence of that allow site-specific conjugation of cytotoxic drugs. Each heavy chain can include a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprising a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Inventors: Bing XIA, Cui FENG, Lixia GU, Chen LI, Yuhong ZHOU, Ziping WEI
  • Publication number: 20230414781
    Abstract: Isolated anti-human B7-H3 antibody includes two heavy chains including a hinge region comprising an amino acid sequence that allows site-specific conjugation of cytotoxic drugs. Each heavy chain includes a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprises a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 28, 2023
    Inventors: Bing XIA, Hao KONG, Lixia CAO, Fangdun JIANG, Yuhong ZHOU, Ziping WEI
  • Publication number: 20210346510
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Application
    Filed: April 12, 2021
    Publication date: November 11, 2021
    Inventors: Yuhong Zhou, Ziping Wei
  • Patent number: 10994021
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: May 4, 2021
    Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
    Inventors: Yuhong Zhou, Ziping Wei
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Publication number: 20150328306
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Application
    Filed: July 13, 2015
    Publication date: November 19, 2015
    Inventors: Guillermo TOUS, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 9096658
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 4, 2015
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Publication number: 20100278929
    Abstract: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
    Type: Application
    Filed: January 19, 2010
    Publication date: November 4, 2010
    Applicant: Medlmmune, LLC
    Inventors: Ziping Wei, Guillermo Tous, Mark Schenerman, Christian B. Allan
  • Publication number: 20100278852
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Application
    Filed: March 5, 2010
    Publication date: November 4, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Guillermo TOUS, Mark SCHENERMAN, Jose CASAS-FINET, Ziping WEI, David PFARR
  • Patent number: 7786273
    Abstract: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: August 31, 2010
    Assignee: Medimmune, LLC
    Inventors: Guillermo I. Tous, Mark Schenerman, Ziping Wei
  • Patent number: 7700720
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: April 20, 2010
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Publication number: 20090030187
    Abstract: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.
    Type: Application
    Filed: March 14, 2006
    Publication date: January 29, 2009
    Inventors: Guillermo I. Tous, Mark Schenerman, Ziping Wei
  • Publication number: 20070110757
    Abstract: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
    Type: Application
    Filed: June 23, 2006
    Publication date: May 17, 2007
    Inventors: Ziping Wei, Guillermo Tous, Mark Schenerman, Christian Allan
  • Publication number: 20060216284
    Abstract: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.
    Type: Application
    Filed: March 14, 2006
    Publication date: September 28, 2006
    Inventors: Guillermo Tous, Mark Schenerman, Ziping Wei
  • Publication number: 20060099220
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Application
    Filed: September 21, 2005
    Publication date: May 11, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 6077939
    Abstract: This invention provides compositions consisting essentially of a polypeptide and a water-soluble polymer covalently bound thereto at the N-terminal .alpha.-carbon atom via a hydrazone or reduced hydrazone bond, or an oxime or reduced oxime bond. This invention also provides methods of making the instant compositions, pharmaceutical compositions comprising same, and kits for use in preparing same.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: June 20, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ziping Wei, Sunitha Menon-Rudolph, Pradip Ghosh-Dastidar